目的 对2019年漯河市中心医院精神科抗抑郁药的使用情况进行分析，为促进临床合理用药提供指导。方法 采用回顾性分析方法，参考世界卫生组织（WHO）的限定日剂量和药品使用说明书，对2019年1～4季度漯河市中心医院精神科抗抑郁药的销售金额、使用频度（DDDs）、日均费用（DDC）及其排序比（B/A）等进行分析。结果 2019年选择性5-羟色胺（5-HT）再摄取抑制剂（SSRIs）、5-HT及去甲肾上腺素（NA）再摄取抑制剂（SNRIs）和NA和特异性5-HT能抗抑郁药（NaSSAs）的销售金额分别位居各季度的前3名，其中SSRIs的构成比最大。销售金额稳居前4位的分别为艾司西酞普兰、舍曲林、米氮平、度洛西汀。DDDs排名前2位的抗抑郁药为艾司西酞普兰、舍曲林。抗抑郁药的DDC比较稳定，度洛西汀、阿戈美拉汀、文拉法辛的DDC最高。艾司西酞普兰、西酞普兰、舍曲林、阿米替林、氯米帕明等些种药物的B/A趋近于1。结论 漯河市中心医院精神科抗抑郁药的结构、层次、使用基本合理，与当前我国抗抑郁药发展形势相符合。

Objective To analyze the utilization of antidepressant drugs in Department of Psychiatry of Luohe Central Hospital in 2019, so as to provide some guidance for promoting rational clinical use. Methods A retrospective analysis was conducted to compare the sales amount, defined daily dose system (DDDs), defined daily cost (DDC), and their ranking ratio (B/A) of antidepressants in Department of Psychiatry of Luohe Central Hospital in the first quarter to the fourth quarter of 2019 by referring to the limited daily dose and drug use manual provided by WHO. Results The sales amount of SSRIs, SNRIs, and NaSSAs were ranked the top three, in which SSRIs had the most composition ratio. The sales amount of escitalopram, sertraline, mirtazapine, and duloxetine were ranked the top four. DDDs of escitalopram and sertraline were ranked the top two. DDC of antidepressant drugs was stable, and DDC of duloxetine, agomelatine, and venlafaxine were ranked the top three. B/A of escitalopram, citalopram, sertraline, amitriptyline, and clomipramine were close to 1. Conclusion The structure, hierarchy, and use of antidepressant drugs in Department of Psychiatry of Luohe Central Hospital are reasonable, which is consistent with the development of antidepressant in China.

R971

河南省科学技术厅项目（172102310616）